Black Cohosh for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Black Cohosh for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A root extract taken for symptoms after menstrual cycling ends. It does not raise estrogen and has not been shown to stir breast or womb tissue. Whether it works is unsettled: independent trials found no benefit, pooled European data report improvement. Sleep shows the steadiest signal. Rare liver injury is the main concern; preparation identity matters more than dose. (Full Review)

Protocol

Standard dose
40 mg daily
Crude-drug-equivalent of a standardized isopropanolic or ethanolic root extract, supplying 1 to 2 mg triterpene glycosides
Single versus split dosing
40 mg once or 20 mg twice daily
Both are used and perform equivalently; split dosing is chosen mainly for gastrointestinal tolerance
Timing
Evening
No circadian dependence is established; evening dosing is common where night sweats dominate, with the evening meal where nausea occurs
Time to effect
Time to effect
4 weeks
Symptom change typically appears at 4 weeks and plateaus by 8 to 12 weeks
Reassessment point
12 weeks
A defined checkpoint separating responders from non-responders, since trial benefit emerges within 4 to 12 weeks
Intended duration
6 months
Not lifelong; European regulatory guidance and most trial protocols limit continuous use to six months, after which reassessment is expected

Benefits

Contraindications
  • Active liver disease, transaminases above twice the upper limit of normal, cirrhosis (any Child-Pugh class), or prior herbal drug-induced liver injury
  • Pregnancy at any stage and throughout lactation
  • Symptomatic bradycardia below 50 beats per minute, second- or third-degree heart block, or an unpaced sinus node disorder
  • Prior hypersensitivity to black cohosh or to any Actaea or Ranunculaceae species
  • Undiagnosed abnormal uterine bleeding, until the cause has been established
    •
Key Interactions
  • Tamoxifen and CYP2D6 substrates
  • Atorvastatin and other statins (cholesterol-lowering drugs)
  • Other hepatotoxic drugs (methotrexate, isoniazid, ketoconazole, amiodarone, high-dose acetaminophen)
  • Rate-slowing cardiac drugs (metoprolol, atenolol, verapamil, diltiazem, digoxin)
  • Serotonergic antidepressants (fluoxetine, sertraline, venlafaxine)
  • Over-the-counter agents (acetaminophen, high-dose niacin, oral contraceptives)
  • Supplement interactions (St John's wort, kava, green tea extract, turmeric, red yeast rice, ashwagandha)
  • Additive supplements (St John's wort, Siberian rhubarb, red clover, soy isoflavones, evening primrose oil, shatavari)
  • Other interventions (systemic hormone therapy)
    •

Risk & Side Effects

  • High: Mild gastrointestinal upset, headache, and rash
    •
  • Medium: Idiosyncratic liver injury; species adulteration in commercial products
  • Low: Symptomatic bradycardia; weight gain
    •
  • Speculative: Genotoxicity through chromosome loss
    •

Monitoring

Marker Target Why
ALT 10–26 U/L (women) Most specific marker of liver cell injury
AST 10–26 U/L Confirms and contextualises an ALT rise
GGT <20 U/L (women) Earliest and most sensitive signal of hepatobiliary stress
ALP 50–90 U/L Distinguishes bile-duct pattern injury from cell injury
Total bilirubin 0.3–1.0 mg/dL Marks the transition from enzyme change to clinical liver failure
Resting heart rate 55–85 bpm Detects the reported bradycardia signal before fainting occurs
FSH No established target; single baseline confirmation only Confirms menopausal stage at baseline; does not track response
Estradiol No established target; track change from own baseline Documents that no estrogenic effect is occurring
TSH 0.5–2.5 mIU/L Rules out thyroid disease mimicking vasomotor symptoms

Cadence: Liver panel and resting heart rate before the first dose; liver enzymes repeated at 4 to 8 weeks, then every 3 to 6 months for as long as use continues; resting heart rate monthly; symptom diary repeated at week 12

Qualitative Assessment

  • Daily hot flash count and severity, recorded rather than recalled
  • Number of night wakings and time to return to sleep
  • Morning refreshment on waking
  • Irritability and mood lability over the preceding week
  • Energy through the afternoon
  • Absence of nausea, upper abdominal discomfort, dark urine or unusual fatigue
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.